Preoperative assessment of hilar cholangiocarcinoma by dual-modality PET/CT
Standard
Preoperative assessment of hilar cholangiocarcinoma by dual-modality PET/CT. / Li, Jun; Kuehl, Hilmar; Grabellus, Florian; Müller, Stephan P; Radunz, Sonia; Antoch, Gerald; Nadalin, Silvio; Broelsch, Christoph E; Gerken, Guido; Paul, Andreas; Kaiser, Gernot M.
In: J SURG ONCOL, Vol. 98, No. 6, 01.11.2008, p. 438-43.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Preoperative assessment of hilar cholangiocarcinoma by dual-modality PET/CT
AU - Li, Jun
AU - Kuehl, Hilmar
AU - Grabellus, Florian
AU - Müller, Stephan P
AU - Radunz, Sonia
AU - Antoch, Gerald
AU - Nadalin, Silvio
AU - Broelsch, Christoph E
AU - Gerken, Guido
AU - Paul, Andreas
AU - Kaiser, Gernot M
N1 - (c) 2008 Wiley-Liss, Inc.
PY - 2008/11/1
Y1 - 2008/11/1
N2 - BACKGROUND: The purpose of the current study was to evaluate the accuracy of (18)F-FDG PET/CT in staging hilar cholangiocarcinoma.MATERIALS AND METHODS: From June 2004 to December 2007, patients evaluated for surgical treatment of hilar cholangiocarcinoma were entered into a prospective database. Dual modality (18)F-FDG PET/CT was performed before surgery. The report was reviewed with comparison to the operative and pathological results in each case for tumour-node-metastasis staging.RESULTS: Seventeen patients (6 women, 11 men) of a median age of 62 years were included in the study. Radical tumour resection was performed on seven patients. Ten patients underwent surgical exploration. The sensitivity of PET/CT in detecting primary tumour was found to be 58.8% (25% in T2 tumour, 70% in T3 tumour, 66.7% in T4 tumour). The sensitivity/specificity of PET/CT in detecting lymph node metastasis and distant metastasis were 41.7%/80% and 55.6%/87.5%, respectively. Positive (18)F-FDG uptake in the bile duct was found to be associated with surgical non-resectability (P = 0.05).CONCLUSION: Dual-modality PET/CT imaging was found to have a high specificity in detection of lymph node and distant metastasis in hilar cholangiocarcinoma, with a limited value in correct judgement of surgical resectability for tumours in stadium UICC I-III.
AB - BACKGROUND: The purpose of the current study was to evaluate the accuracy of (18)F-FDG PET/CT in staging hilar cholangiocarcinoma.MATERIALS AND METHODS: From June 2004 to December 2007, patients evaluated for surgical treatment of hilar cholangiocarcinoma were entered into a prospective database. Dual modality (18)F-FDG PET/CT was performed before surgery. The report was reviewed with comparison to the operative and pathological results in each case for tumour-node-metastasis staging.RESULTS: Seventeen patients (6 women, 11 men) of a median age of 62 years were included in the study. Radical tumour resection was performed on seven patients. Ten patients underwent surgical exploration. The sensitivity of PET/CT in detecting primary tumour was found to be 58.8% (25% in T2 tumour, 70% in T3 tumour, 66.7% in T4 tumour). The sensitivity/specificity of PET/CT in detecting lymph node metastasis and distant metastasis were 41.7%/80% and 55.6%/87.5%, respectively. Positive (18)F-FDG uptake in the bile duct was found to be associated with surgical non-resectability (P = 0.05).CONCLUSION: Dual-modality PET/CT imaging was found to have a high specificity in detection of lymph node and distant metastasis in hilar cholangiocarcinoma, with a limited value in correct judgement of surgical resectability for tumours in stadium UICC I-III.
KW - Bile Duct Neoplasms
KW - Bile Ducts, Intrahepatic
KW - Cholangiocarcinoma
KW - Female
KW - Fluorodeoxyglucose F18
KW - Humans
KW - Male
KW - Middle Aged
KW - Neoplasm Metastasis
KW - Neoplasm Staging
KW - Positron-Emission Tomography
KW - Preoperative Care
KW - Prospective Studies
KW - Radiopharmaceuticals
KW - Sensitivity and Specificity
KW - Tomography, X-Ray Computed
KW - Journal Article
U2 - 10.1002/jso.21136
DO - 10.1002/jso.21136
M3 - SCORING: Journal article
C2 - 18767120
VL - 98
SP - 438
EP - 443
JO - J SURG ONCOL
JF - J SURG ONCOL
SN - 0022-4790
IS - 6
ER -